AUTHORS
Christodoulos Pipinikas, PhD, Madhuri Paul, PhD2, Roisin Puentes, PharmD, PhD3, Jonathan Feld, MD4, John M. Furgason, PhD5, Amber Chevalier, N/A6, Derek Lyle, MD7
AFFILIATIONS
1 NeoGenomics Laboratories, Inc., Fort Myers, Florida, United States
2 NeoGenomics Laboratories, Inc., Fort Myers, Florida, United States
3 NeoGenomics Laboratories, Inc., Fort Myers, Florida, United States
4 Moffitt Malignant Hematology & Cellular Therapy Center, Memorial Healthcare System, Pembroke Pines, Florida, United States
5 NeoGenomics Laboratories, Inc., Fort Myers, Florida, United States
6 NeoGenomics Laboratories, Inc., Fort Myers, Florida, United States
7 NeoGenomics Laboratories, Inc., Fort Myers, Florida, United States
ABSTRACT
Introduction: Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) comprise a closely related group of highly heterogenous myeloid malignancies. As clinical outcomes depend heavily on the underlaying molecular profiles, genomic testing is essential for diagnosis, risk stratification and therapy selection. Comprehensive genomic profiling (CGP) using next-generation sequencing (NGS) either on peripheral blood (PB) or bone marrow (BM), enables accurate and timely identification of clinically relevant alterations. This facilitates refined diagnosis, improved prognostic assessment, and more informed, individualized management decisions. In this study, we leverage real world genomic data to decipher the mutational landscape of AML and MDS and describe the detection frequency of alterations amenable by targeted therapies.
Methods:Patients (pts) were tested with NeoGenomics’ NeoComprehensive Heme Cancers or Myeloid Disorders CGP assays between 03/2023 and 06/2026. Both utilize NGS to interrogate DNA (SNVs/InDels, CNVs) and RNA (fusions and rearrangements) alterations across 433 and 164 genes, respectively, for diagnostic evaluation, prognosis, risk stratification, and therapy guidance.
Results: The study included 44,274 unique pts; 34,438 MDS pts (including 30,863 with isolated MDS; 69.7% of the entire cohort) and 13,411 AML pts (including 9,836 with isolated AML; 22.2%). A subset of 3,575 pts (8.1%) was captured in both groups due to overlapping diagnostic features or disease progression from MDS to AML. Patients were tested with the NeoComprehensive Heme Cancers (35,833; 80.9%), NeoComprehensive Myeloid Disorders (7,380; 16.7%) or both assays (1,061; 2.4%). Medical records were available from the Healthcare Information Exchange using the xCures® platform for 11,393 pts (26%) between 9/2025 to 6/2026. Within this subset, 3,588 pts remained treatment-naïve (31.5%) while the remaining 7,805 (68.5%) received various prior treatments.
AML pts exhibited a substantially higher prevalence for fusions (14.8%; N=1,985 vs 2.1%; N=711) and CNVs (17.3%; N=2,315 vs 5.5%; N=1,901 in MDS). SNVs/InDels were the most frequent alteration in both groups, though more prevalent in AML (95.8%; N=12,843 vs 88.1%; N=30,335 in MDS). Distinct differences were also seen in variant classification. Variants of uncertain significance (VUS) were more frequently detected in AML (81.2%; N=10,892 vs 76.5%; N=26,347 in MDS) while pathogenic or likely pathogenic (P/LP) variants were identified in a much higher proportion of AML pts (85.6%; N=11,482) compared to MDS (55.3%; N=19,033). Investigation of the top 15 genes with P/LP variants revealed distinct yet overlapping mutational profiles, reflecting their shared myeloid lineage but different clinical characteristics. In AML, TET2 (17.9%), TP53 (17.5%), ASXL1 (17.3%), and DNMT3A (16.3%) were the most frequently mutated genes while TET2 (15.4%), ASXL1 (12%) and SF3B1 (8.8%) in MDS. Notably, several key drivers exhibited a significantly higher mutational frequency in AML including TP53, DNMT3A and IDH2 (17.5%, 16.3% and 9.6% in AML vs 7.7%, 8.6% and 2.3% in MDS). Proliferation and differentiation-associated genes like FLT3 (12.6%) and NPM1 (11%) as well as IDH1 (5.5%) and BCOR (5.2%) were limited to AML whereas classic chronic or clonal hematopoiesis-associated markers like JAK2 (4.6%), PPM1D and CBL (both 2%) were limited to MDS.
Conclusions: In this study, CGP testing identified P/LP variants in 69% of patients, including patients with variants in genes directly targeted by FDA-approved therapies (NPM1, FLT3, IDH1/2, SF3B1) or currently being evaluated in clinical trials (TP53, JAK2, RAS pathway). Results reiterate that the AML genomic landscape is characterized not only by an enrichment of genomic alterations but also by a significantly higher burden of pathogenic and potentially clinically actionable mutations relative to MDS. Furthermore, epigenetic regulators (TET2, ASXL1) serve as a common trunk for both diseases, while accelerated frequencies of TP53 and DNMT3A abnormalities, coupled with the emergence of FLT3 and NPM1 mutations, distinguish the molecular profile of AML from MDS. Additional data including separate investigation of the mutational landscape in those cases with either overlapping diagnosis or MDS pts transforming into AML as well as treatment response across different treatment modalities stratified by disease subgroups and mutational profiles will be presented during the meeting.
DISCLOSURES
Amber Chevalier, N/A: NeoGenomics Laboratories, Inc. - Stock (publicly traded); NeoGenomics Laboratories, Inc. - Current Employment